<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03978234</url>
  </required_header>
  <id_info>
    <org_study_id>UFAI-PF-01</org_study_id>
    <nct_id>NCT03978234</nct_id>
  </id_info>
  <brief_title>Evaluating the Safety and Effect of abobotulinumtoxinA in the Gastrocnemius Muscle to Improve Equinus and Plantar Fasciitis Pain</brief_title>
  <official_title>A Phase II Clinical Trial Evaluating the Safety and Effect of abobotulinumtoxinA Injection in the Gastrocnemius Muscle to Improve Equinus and Associated Plantar Fasciitis Pain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Foot and Ankle Foundation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Foot and Ankle Foundation</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research is to collect safety and efficacy data on injection of&#xD;
      botulinumtoxinA (AbobotulinumtoxinA /Dysort) into the gastrocnemius (calf) muscle to improve&#xD;
      equinus (lack of flexibility to bring the top of the foot towards the front of the leg) in&#xD;
      subjects with plantar fasciitis and relieve pain associated with this condition. The use of&#xD;
      AbobotulinumtoxinA is considered experimental in this study because it has not been approved&#xD;
      by the United States Food and Drug Administration (FDA) for the treatment of plantar&#xD;
      fasciitis.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 20, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">October 31, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>injection</measure>
    <time_frame>8 weeks</time_frame>
    <description>Reduction of pain (VAS scale) associated with plantar fasciitis at 8 weeks post injection</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>26 weeks</time_frame>
    <description>Number of product related AEs per patient that are definitely, probably, or possibly related to the product post-injection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PROMIS Pain intensity instrument</measure>
    <time_frame>26 weeks</time_frame>
    <description>Changes in PROMIS Pain Intensity Instrument,</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PROMIS Pain interference instrument</measure>
    <time_frame>26 weeks</time_frame>
    <description>Changes in PROMIS Pain Interference Instrument</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PROMIS Physical function Instrument</measure>
    <time_frame>26 weeks</time_frame>
    <description>Changes in PROMIS Physical function instrument</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AOFAS Ankle-Hindfoot Score</measure>
    <time_frame>26 weeks</time_frame>
    <description>Changes in the American Orthopaedic Foot and Ankle Society Ankle-Hindfoot Score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FAAM Foot and Ankle Ability Measure</measure>
    <time_frame>26 weeks</time_frame>
    <description>Changes in the Foot and Ankle Ability Measure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gastrocnemius measurement</measure>
    <time_frame>26 weeks</time_frame>
    <description>Changes in gastrocnemius muscle size using ultrasonography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gastrocnemius measurement and mobility</measure>
    <time_frame>26 weeks</time_frame>
    <description>Changes in gastrocnemius range of motion/dorsiflexion using goniometer</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Plantar Fasciitis</condition>
  <condition>Plantar Fasciitis, Chronic</condition>
  <condition>Plantar Fasciitis of Both Feet</condition>
  <arm_group>
    <arm_group_label>Single group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single group</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AbobotulinumtoxinA 300 UNT</intervention_name>
    <description>AbobotulinumtoxinA 300 UNT</description>
    <arm_group_label>Single group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. At least 18 years old and not older than 75 years.&#xD;
&#xD;
          2. History of Plantar fasciitis for a minimum of 6 weeks&#xD;
&#xD;
          3. History and physical examination consistent with plantar fasciitis and a diagnostic&#xD;
             ultrasound study showing thickening of the plantar fascia &gt;5 mm (normal is 3 mm)&#xD;
&#xD;
          4. Minimum Visual Analog Scale (VAS) score of 4.&#xD;
&#xD;
          5. Failed conservative care with at least two of the following treatments: Stretching,&#xD;
             rest, shoe modifications, insoles or orthotics, physical therapy, or cortisone&#xD;
             injection.&#xD;
&#xD;
          6. Females of childbearing potential must be willing to use acceptable methods of&#xD;
             contraception (birth control pills, barriers or abstinence) during the course of the&#xD;
             study and undergo pregnancy tests.&#xD;
&#xD;
          7. Subject understands and is willing to participate in the clinical study and can comply&#xD;
             with visit and post -injection questionnaire schedules.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients with history of diabetes, back issues, nerve issues or previous surgery of&#xD;
             the foot or calf.&#xD;
&#xD;
          2. Patients with no pain in the heel region.&#xD;
&#xD;
          3. Subject is pregnant or breast- feeding.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Babak Baravarian, DPM</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Foot &amp; Ankle Foundation</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Maha K Curley, CRC</last_name>
    <phone>310-828-0011</phone>
    <phone_ext>1007</phone_ext>
    <email>mahak@footankleinstitute.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University Foot &amp; Ankle Institute</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90403</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maha K. Curley, CRC</last_name>
      <email>mahak@footanklesintitute.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://footankleinstitute.com</url>
    <description>Related Info</description>
  </link>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>May 23, 2019</study_first_submitted>
  <study_first_submitted_qc>June 4, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 7, 2019</study_first_posted>
  <last_update_submitted>September 22, 2020</last_update_submitted>
  <last_update_submitted_qc>September 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Foot and Ankle Foundation</investigator_affiliation>
    <investigator_full_name>Maha K. Curley</investigator_full_name>
    <investigator_title>Study Coordinator</investigator_title>
  </responsible_party>
  <keyword>Heel pain</keyword>
  <keyword>Plantar Fasciitis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fasciitis</mesh_term>
    <mesh_term>Fasciitis, Plantar</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>abobotulinumtoxinA</mesh_term>
    <mesh_term>Botulinum Toxins, Type A</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

